연구동향 분석

Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs

Hyo Jin Kim Sang Soo Kim Sang Heon Song 2022년

논문상세정보
인용/피인용
' Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • diabetic nephropathies
  • glomerular filtration rate
  • hypoglycemicagents
  • treatment outcome
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
282 0

0.0%

' Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs' 의 참고문헌

  • Young-onset type 2 diabetes in South Korea: a review of the current status and unmet need
  • Why do young people with chronic kidney disease die early?
    Kumar S [2014]
  • Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice
    Nistor I [2017]
  • Updating the natural history of diabetic nephropathy
    Pugliese G [2014]
  • Trends in the incidence and prevalence of end-stage renal disease with hemodialysis in entire Korean population: a nationwide population-based study
    Choi HS [2021]
  • Trends in the Incidence, Prevalence, and Mortality of End-Stage Kidney Disease in South Korea
    이민정 [2020]
  • Treatment of diabetic kidney disease: current and future targets
    김미경 [2017]
  • Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment
  • The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy
    Mogensen CE [1983]
  • The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
    Kanasaki K [2018]
  • The role of inflammation in diabetic kidney disease
  • The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
  • The protective roles of GLP-1R signaling in diabetic nephropathy : possible mechanism and therapeutic potential
    Fujita H [2014]
  • The potential for renoprotection with incretin-based drugs
    Tanaka T [2014]
  • The mode of action of caffeine on catecholamine release from perfused adrenal glands of cat
    Yamada Y [1989]
  • The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group
    Klahr S [1994]
  • The effect of liraglutide on renal function : a randomized clinical trial
  • The clinical course of diabetic nephropathy
    Kussman MJ [1976]
  • Temporal adjustment of the juxtaglomerular apparatus during sustained inhibition of proximal reabsorption
    Thomson SC [1999]
  • Surrogate end points for clinical trials of kidney disease progression
    Stevens LA [2006]
  • Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
    Takashima S [2016]
  • Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement
    오태정 [2020]
  • Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
    Cherney DZ [2014]
  • Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
    Marso SP [2016]
  • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    Scirica BM [2013]
  • SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes : a systematic review and meta-analysis
    Neuen BL [2019]
  • SGLT2 inhibitors and GLP-1 receptor agonists : established and emerging indications
    Brown E [2021]
  • Risk factors for renal dysfunction in type 2 diabetes : U. K. Prospective Diabetes Study 74
  • Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
    Heerspink H [2018]
  • Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
    DeFronzo RA [2017]
  • Renal outcomes of antidiabetic treatment options for type 2 diabetes : a proposed MARE definition
    Prischl FC [2018]
  • Renal outcomes in type 2diabetes : a review of cardiovascular and renal outcome trials
    Williams DM [2020]
  • Renal function in diabetic disease models : the tubular system in the pathophysiology of the diabetic kidney
    Vallon V [2012]
  • Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes : a 12-week, randomized, double-blind, placebo-controlled trial
    Tonneijck L [2016]
  • Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2diabetes and nephropathy : results from the DIAMETRIC(Diabetes Mellitus Treatment for Renal Insufficiency Consortium)database
    Packham DK [2012]
  • Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria
    Vistisen D [2019]
  • Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes
    Jiang G [2019]
  • Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group
    Breyer JA [1996]
  • Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study
  • Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function
    Zoppini G [2012]
  • Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine : an 8-week, randomised, open-label trial
    Tonneijck L [2017]
  • Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials : a statistical simulation
    Greene T [2019]
  • Patterns of estimated glomerular filtration rate decline leading to end-stage renal disease in type 1 diabetes
    Skupien J [2016]
  • Patterns and predictors of kidney function decline in the last year prior to dialysis
    Ambrogi V [2009]
  • Pathophysiology of diabetic kidney disease : impact of SGLT2 inhibitors
    DeFronzo RA [2021]
  • New therapeutic agents in diabetic nephropathy
    김예니 [2017]
  • Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
    Rieg T [2012]
  • Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
  • Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients
  • Measured and estimated glomerular filtration rate : current status and future directions
    Levey AS [2020]
  • Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients : an indicator of more advanced glomerular lesions
    Caramori ML [2003]
  • Longitudinal progression trajectory of GFR among patients with CKD
    Li L [2012]
  • Longitudinal estimated GFR trajectories in patients with and without type 2diabetes and nephropathy
  • Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice
    Park CW [2007]
  • Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes : a prospective pilot study
    Rizzo M [2015]
  • Liraglutide and renal outcomes in type 2 diabetes
    Mann J [2017]
  • Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease
    Rigalleau V [2010]
  • KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
  • Interlaboratory variability in plasma creatinine measurement and the relation with estimated glomerular filtration rate and chronic kidney disease diagnosis
    Lee E [2017]
  • Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
    Oshima M [2021]
  • Impact of chronic kidney disease on mortality: A nationwide cohort study
    김경민 [2019]
  • How do kidneys adapt to a deficit or loss in nephron number?
    Fattah H [2019]
  • Hemodynamically mediated glomerular injury and the progressive nature of kidney disease
    Brenner BM [1983]
  • Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat
    Thomson SC [2013]
  • Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment : are they all the same
  • Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
  • Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis
    Thomson SC [2008]
  • GLP-1 and the kidney : from physiology to pharmacology and outcomes in diabetes
    Muskiet M [2017]
  • Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria
    Zhang H [2012]
  • Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition
    Bunck MC [2010]
  • Executive summary of the 2020 KDIGO diabetes management in CKD guideline : evidence-based advances in monitoring and treatment
    de Boer IH [2020]
  • Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials : an individual participant meta-analysis of observational data
    Grams ME [2019]
  • Empagliflozin and progression of kidney disease in type 2 diabetes
    Wanner C [2016]
  • Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes : a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials
    Mann J [2020]
  • Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
    Holman RR [2017]
  • Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease : an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
    Cherney DZI [2017]
  • Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes : an analysis from the DECLARE-TIMI 58 randomised trial
    Mosenzon O [2019]
  • Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
    배재현 [2019]
  • Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes : outcomes from TECOS
    Cornel JH [2016]
  • Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
    Green JB [2015]
  • Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial
    Mosenzon O [2017]
  • Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk : a post hoc analysis of the EXSCEL trial
  • Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk : the CARMELINA randomized clinical trial
  • Effect of estimating equations for glomerular filtration rate on novel surrogate markers for renal outcome
    Kim Kipyo [2021]
  • Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes : post-hoc renal analysis of the DEPICT randomised controlled trials
    Groop PH [2020]
  • Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria : data from the CANVAS program
    Neuen BL [2019]
  • Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial
  • Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria
  • Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease(AWARD-7) : a multicentre, open-label, randomised trial
    Tuttle KR [2018]
  • Dulaglutide and renal outcomes in type 2 diabetes : an exploratory analysis of the REWIND randomised, placebo-controlled trial
    Gerstein HC [2019]
  • Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis
  • Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α1-67 in patients with type 2 diabetes
    Lovshin JA [2017]
  • Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study
    Molitch ME [2010]
  • Dapagliflozin suppresses hepcidin and increases erythropoiesis
    Ghanim H [2020]
  • Dapagliflozin in patients with chronic kidney disease
  • Current findings of kidney biopsy including nephropathy associated with hypertension and diabetes mellitus in Korea
    Kipyo Kim [2020]
  • Composing a new song for trials : the Standardized Outcomes in Nephrology(SONG)initiative
    Tong A [2017]
  • Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014
    Afkarian M [2016]
  • Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation
    Heerspink H [2021]
  • Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
    Kraus BJ [2021]
  • Changes in diabetes-related complications in the United States, 1990-2010
    Gregg EW [2014]
  • Changes in albuminuria but not GFR are associated with early changes in kidney structure in type 2 diabetes
    Looker HC [2019]
  • Change in albuminuria as a surrogate endpoint for progression of kidney disease : a meta-analysis of treatment effects in randomised clinical trials
  • Canagliflozin reduces inflammation and fibrosis biomarkers : a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
  • Canagliflozin and renal outcomes in type 2 diabetes : results from the CANVAS Program randomised clinical trials
    Perkovic V [2018]
  • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    Neal B [2017]
  • Aspiration : cause and implications
    Lundy DS [1999]
  • Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
    고승현 [2017]
  • Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
    Barnett AH [2004]
  • Analysis of mortality risk from Korean hemodialysis registry data 2017
    진동찬 [2019]
  • An integrative systems biology approach for precision medicine in diabetic kidney disease
    Mulder S [2018]
  • Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    White WB [2013]
  • Age-and gender-specific reference values of estimated GFR in Caucasians : the Nijmegen Biomedical Study
    Wetzels JF [2007]
  • Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
    Zhou X [2015]
  • A model for a proportional treatment effect on disease progression
    Greene T [2001]
  • 11. Microvascular complications and foot care : standards of medical care in diabetes-2021